4 Arthritis Drug Stocks Investors Should Monitor for Growth PotentialZacks Investment Research • 10/27/26
AbbVie: Analyzing Performance, Pipeline, And Pricing Ahead Of Q3 (Strong Buy)Seeking Alpha • 10/27/26
Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA)PRNewsWire • 10/27/26
AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple MyelomaPRNewsWire • 10/27/26
Allergan Aesthetics Celebrates Eight Years of Engaging Girls in STEM Through Continued Partnership with Girls Inc.PRNewsWire • 10/26/26
AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 3024/7 Wall Street • 10/26/26
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's DiseasePRNewsWire • 10/23/26
Forget Chasing 7% Yields: These 5 Dividend Stocks Offer Something Different24/7 Wall Street • 10/23/26
BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential?Zacks Investment Research • 10/23/26
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 10/23/26
AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True?Zacks Investment Research • 10/22/26
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combinationReuters • 10/22/26
AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis SuppurativaPRNewsWire • 10/22/26
These 3 Dividend Stocks Paid Out Over 90% of Free Cash Flow, but 1 Has Raised Its Dividend 54 Years in a Row24/7 Wall Street • 10/22/26
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 10/21/26